Psyence Biomedical Ltd
PBM4.460USD
+2.100+88.98%
Horário de mercado （ET）Cotações atrasadas em 15 min
99.91KValor de mercado
PerdaP/L TTM
Mais detalhes de Psyence Biomedical Ltd Empresa
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Informações da empresa
Código da empresaPBM
Nome da EmpresaPsyence Biomedical Ltd
Data de listagemDec 10, 2021
CEODr. Neil Maresky
Número de funcionários12
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 10
Endereço121 Richmond Street West Penthouse
CidadeTORONTO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalM5H 2K1
Telefone17744604171
Site
Código da empresaPBM
Data de listagemDec 10, 2021
CEODr. Neil Maresky
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 9 de jul
Atualizado em: qua, 9 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Parallel Advisors, LLC
38.56%
Sabby Management, LLC
4.52%
White Lion Capital LLC
1.76%
Citadel Advisors LLC
1.32%
Essential Planning, LLC
1.29%
Other
52.55%
Investidores
Investidores
Proporção
Parallel Advisors, LLC
38.56%
Sabby Management, LLC
4.52%
White Lion Capital LLC
1.76%
Citadel Advisors LLC
1.32%
Essential Planning, LLC
1.29%
Other
52.55%
Tipos de investidores
Investidores
Proporção
Investment Advisor
41.14%
Investment Advisor/Hedge Fund
4.52%
Venture Capital
1.83%
Hedge Fund
1.55%
Research Firm
0.64%
Corporation
0.48%
Other
49.83%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
45
357.80K
50.17%
+182.18K
2025Q1
45
167.96K
26.60%
+69.68K
2024Q4
82
948.20K
24.27%
+587.08K
2024Q3
88
169.92K
15.90%
-186.51K
2024Q2
92
159.62K
36.84%
-203.47K
2024Q1
96
157.41K
35.61%
-211.56K
2023Q4
88
18.95K
16.18%
-253.66K
2023Q3
87
16.58K
55.18%
-252.44K
2023Q2
86
17.96K
50.97%
-264.02K
2023Q1
85
19.55K
55.14%
-329.89K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Sabby Management, LLC
32.21K
4.52%
+32.21K
--
Mar 31, 2025
White Lion Capital LLC
12.55K
1.76%
+12.55K
--
Dec 04, 2024
Citadel Advisors LLC
9.45K
1.32%
+8.01K
+555.34%
Mar 31, 2025
Essential Planning, LLC
9.19K
1.29%
+9.19K
--
Dec 31, 2024
Virtu Americas LLC
4.58K
0.64%
+2.98K
+187.50%
Mar 31, 2025
AdvisorShares Investments, LLC
4.45K
0.62%
+1.07K
+31.71%
Mar 31, 2025
UBS Financial Services, Inc.
4.21K
0.59%
+2.62K
+164.01%
Mar 31, 2025
Launchpad Ignition Holdings LLC
2.00K
0.28%
+2.00K
--
Mar 31, 2024
Two Sigma Investments, LP
1.62K
0.23%
+1.62K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
AdvisorShares Psychedelics ETF
0.22%
AdvisorShares Psychedelics ETF
Proporção0.22%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Data
Tipo
Proporção
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
Nov 12, 2024
Merger
75<1
